Summary
Kristopher Hanson, who serves as General Counsel at MapLight Therapeutics (NASDAQ: MPLT), completed three sales of company common stock on April 15 and 16, 2026, disposing of a combined 1,827 shares and receiving $49,134 in proceeds. The trades occurred in multiple tranches and were executed at a range of prices. After the transactions, Hanson directly holds 190,165 MapLight shares, a total that includes 410 shares purchased through the issuer’s stock purchase plan on March 31, 2026.
Transaction details
- Total shares sold: 1,827 Voting Common Stock shares.
- Total proceeds: $49,134.
- Dates of sale: April 15 and April 16, 2026.
- April 15 activity: 1,529 shares sold in multiple transactions at prices ranging from $26.33 to $27.29.
- April 16 activity: two sets of sales - 73 shares sold at prices ranging from $26.2201 to $27.2197, and 225 shares sold at prices ranging from $27.22 to $27.9898.
- Post-sale direct ownership: 190,165 shares, which incorporates 410 shares acquired under the Issuer’s stock purchase plan on March 31, 2026.
Share price and recent performance
Since the disclosed sales, MapLight’s stock has risen to $30.05 and is trading close to its 52-week high of $31.13. Year-to-date performance shows shares up 71 percent.
Third-party analysis and technical view
InvestingPro’s evaluation noted that the stock currently appears overvalued and that technical indicators point to overbought conditions. The platform also lists 12 additional ProTips for MPLT, intended to provide further perspective on the company’s financial and market position.
Analyst attention and program milestones
MapLight has attracted recent analyst coverage amid expectations for upcoming clinical data. TD Cowen initiated coverage with a buy rating, calling attention to MapLight’s pipeline targeting central nervous system and neuropsychiatric conditions. TD Cowen specifically highlighted the company’s lead candidate, ML-007C-MA, which the firm indicated is anticipated to present phase II data in the third quarter of this year and is being positioned to improve on Cobenfy’s profile in schizophrenia treatment.
Stifel also remained constructive, reiterating a buy rating and maintaining a $28.00 price target after MapLight’s fourth-quarter update. Stifel stated that phase 2 data for ML-007C-MA is on track for a topline readout in the third quarter of 2026. The firm noted that the M1/M4 mechanism is considered de-risked by Cobenfy and said it will be looking for confirmation of efficacy along with any differentiation related to tolerability, safety, or once-daily dosing.
Context and implications
The insider sales represent a modest portion of Hanson’s overall stake in the company based on the reported post-transaction holdings. The combination of insider activity, technical signals, and active analyst coverage places MapLight under focused market scrutiny in the run-up to the expected phase II topline data.